CompletedPhase 2

Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

Germany28 participantsStarted 2011-05

Plain-language summary

The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * relapsed nodular lymphocyte predominant hodgkin lymphoma * age 18 - 75 * review of diagnosis by experienced pathologist * no major organ dysfunction Exclusion Criteria: * classical hodgkin lymphoma * CD20 antibody treatment within the last 6 months prior enrollment * chronic or current infectious disease requirering systemic antibiotics * other past or current malignancy

What they're measuring

Overall response rate

Timeframe: 12 months after end of treatment

Trial details

NCT IDNCT01187303

SponsorUniversity of Cologne

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-11

View on ClinicalTrials.gov More Relapsed NLPHL trials